NADPH Oxidase Correction in mRNA Transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)
-
- STATUS
- Recruiting
-
- End date
- Jul 1, 2026
-
- participants needed
- 25
-
- sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Summary
- Background
CGD is caused by a gene mutation. For people with CGD, their cells cannot kill germs well, so they can get frequent or life-threatening infections. Researchers want to see if a new procedure can help a person s cells kill germs for a short time. It uses messenger RNA (mRNA) to deliver correct instructions for the gene mutation to the cells.
- Objective
To test a procedure in which mRNA is added to a person s blood cells.
- Eligibility
Males aged 18-75 with CGD with a mutation in the gene that makes the protein gp91phox.
- Design
Participants will be screened with:
Medical history
Physical exam
Blood and urine tests
Swab to test for strep throat
Some screening tests will be repeated during the study.
Participants will be admitted to the NIH Clinical Center hospital for at least 7 days. They will have apheresis. For this, a medicine is injected under their skin to prepare their white blood cells for collection. An IV line is placed into an arm vein. Blood goes through the IV line into a machine that divides whole blood into red blood cells, plasma, and white blood cells. The white blood cells are removed, and the rest of the blood is returned to the participant through an IV line in their other arm. The next day, they will get their mRNA-corrected cells via IV. They will be monitored for 3 more days.
After discharge, participants will keep a symptom diary. They will be contacted weekly for one month, and then once a month. They will have a follow-up visit 3 months after the infusion.
Description
Study Design:
This is a phase 1, open-label, dose-escalation trial to assess the safety and feasibility of administering gp91-Grans to adult patients with X-linked CGD and to identify the maximum tolerated dose (MTD). Subjects will undergo granulocyte-enriched apheresis to provide cell product for mRNA-correction and then receive 1 administration of study agent. The first subjects enrolled will receive the study agent at the lowest dose, and when a level has been determined to be safe, the dose level will be increased to a second and then third dose level for subsequent subjects.Subjects will be hospitalized for at least 3 days after study agent administration and will return for a final study visit about 3 months after administration. Blood will be collected regularly for safety and research evaluations. The study hypothesis is that it is safe and feasible to administer mRNA-transfected autologous granulocyte-enriched apheresis product to restore protein expression and phagocyte nicotinamide adenine dinucleotide phosphate (NADPH) oxidase function in patients with CGD.
Study Agent Description:
The study agent is one administration of autologous CGD gp91mRNA transfected granulocyte-enriched cells, referred to as gp91-Grans. The study agent is derived from apheresis product enriched for granulocytes, which are then transfected with CYBB
gp91 mRNA and administered as an intravenous (IV) infusion.Gp91-Grans will be evaluated using the 3+3 modified Fibonacci model at the following 3 escalating dosages:
Dose K: 1(SqrRoot) 106 granulocyte-enriched cells/kg body mass
Dose K+1: 1(SqrRoot) 107 granulocyte-enriched cells/kg body mass
Dose K+2: 1-5(SqrRoot) 108 granulocyte-enriched cells/kg body mass
Each dose will be evaluated in at least 3 subjects. Dose escalation will be managed by a predetermined algorithm depending on the occurrence of drug-related toxicity (DRT). There will be at least 1 week between study agent administration to each subject.
Primary Objectives:
- Determine the safety and feasibility of gp91-Grans infusion.
- Determine an MTD for administration.
Secondary Objectives:
- Assess efficacy of gp91-Grans at restoring NADPH oxidase.
- Determine the kinetics of gp91-Grans.
Exploratory Objectives:
- Assess for inflammatory responses to gp91-Grans infusion.
- Assess for immune responses to protein expressed by the transfected mRNA.
- Evaluate in vitro bactericidal activity of gp91-Grans.
Primary Endpoints:
- Determine safety and feasibility by:
Safety: Frequency of grade 3 or greater adverse events (AEs) or serious adverse events (SAEs) related to the study agent.
Feasibility: Recruitment, implementation, and manufacturing of gp91-Grans for infusions.
2. MTD determination based on the rate of AEs. MTD is defined as the highest dose level that does not cause the same grade 3 or 4 AEs in 3 or more patients.
Secondary Endpoints:
- Determine percent of circulating dihydrorhodamine (DHR) positive granulocytes following study agent infusion.
- Serial measurement of circulating DHR+ granulocytes from peripheral blood until day 3 following study agent infusion or disappearance of DHR+ granulocytes.
Exploratory Endpoint:
- Assess for increased expression of inflammation-related genesafter study agent infusion.
- Evaluate for development of antibodies against mRNA-expressed gp91phox.
- Perform in vitro bactericidal activity of gp91-Grans.
Details
| Condition | Chronic Granulomatous Disease, Infection |
|---|---|
| Treatment | gp91 Grans |
| Clinical Study Identifier | NCT05189925 |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Last Modified on | 27 October 2022 |
Eligibility
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer